What are the recommended dosing regimens, treatment duration, monitoring requirements, and contraindications for oral terbinafine in treating onychomycosis and acute dermatophyte skin infections in adults and children?

Terbinafine for Onychomycosis and Dermatophyte Infections

For dermatophyte onychomycosis, oral terbinafine 250 mg daily is the first-line treatment: 6 weeks for fingernails and 12 weeks for toenails, with superior efficacy and tolerability compared to all alternatives. 1, 2

Dosing Regimens

Adults - Standard Continuous Therapy

• Fingernail onychomycosis: 250 mg once daily for 6 weeks 1, 2
• Toenail onychomycosis: 250 mg once daily for 12-16 weeks 1, 2
• Re-evaluate patients 3-6 months after treatment initiation; continue treatment if disease persists 1

Pediatric Dosing (Ages 1-12 years)

Weight-based dosing for children 1:

• <20 kg: 62.5 mg daily
• 20-40 kg: 125 mg daily
• >40 kg: 250 mg daily
• Duration: 6 weeks for fingernails, 12 weeks for toenails

Important caveat: Terbinafine is not licensed for pediatric onychomycosis, requiring baseline monitoring even though it's recommended as first-line 1.

Pulse Therapy Considerations

While some studies suggest pulse regimens (500 mg daily for 1 week per month), the evidence is contradictory. One 2004 study showed pulse therapy was at least as effective as continuous dosing 3, but a more recent 2023 study demonstrated continuous therapy achieved 76.67% clinical cure versus only 26.67% with pulse therapy 4. Given this conflicting evidence and the superior outcomes with continuous therapy in the most recent study, standard continuous dosing remains the recommended approach 1, 4.

Monitoring Requirements

Baseline Testing

Obtain before initiating treatment 1:

• Liver function tests (ALT and AST)
• Complete blood count

Additional Baseline Monitoring Indicated For:

• Heavy alcohol consumption history
• Hepatitis or pre-existing liver disease
• Haematological abnormalities
• All pediatric patients (due to unlicensed use) 1

Ongoing Monitoring

No routine monitoring is required for patients without risk factors. However, monitor liver function tests if 1:

• Pre-existing deranged results
• Continuous therapy exceeding 1 month
• Concomitant hepatotoxic drug use

Contraindications

Absolute Contraindications

• History of allergic reaction to oral terbinafine (risk of anaphylaxis) 2
• Active or chronic liver disease 1

Relative Contraindications/Cautions

• Hepatic impairment 1
• Renal impairment (terbinafine clearance decreased in severe kidney disease) 1
• Immunocompromised status 2
• Lupus erythematosus (can aggravate or trigger lupus-like syndrome) 1, 2
• Psoriasis (can aggravate) 1

Critical Safety Warnings

Discontinue Immediately If:

1. Hepatotoxicity signs: Persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools 1, 2
2. Taste disturbance: Can be severe, prolonged, or permanent - patients must be warned of this risk 1, 2
3. Smell disturbance/loss: May be prolonged or permanent 2
4. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, DRESS syndrome, or signs of hives, mouth sores, blistering/peeling skin 1, 2
5. Severe neutropenia: If neutrophil count ≤1,000 cells/mm³ 2
6. Depressive symptoms: Monitor for new onset or worsening depression 2

Common Adverse Effects

Most frequent (>2% incidence) 2:

• Gastrointestinal (49%): nausea, diarrhea, dyspepsia, abdominal pain, flatulence
• Dermatological (23%): rash, pruritus, urticaria, eczema
• Headache
• Liver enzyme abnormalities
• Taste disturbance

Serious adverse events occur in only 0.04% of patients 1.

Drug Interactions

Terbinafine has minimal drug interactions - a major advantage over azoles 1. The only clinically significant interaction is with drugs metabolized by cytochrome P450 2D6 isoenzyme 1, 2. This includes desipramine, certain beta-blockers, and some antipsychotics.

Minor interactions documented with: cimetidine, fluconazole, cyclosporine, rifampin, and caffeine 2.

Efficacy Data Supporting First-Line Status

Terbinafine demonstrates superior efficacy to all alternatives 1, 5:

• Complete cure rate: 55% vs 26% for itraconazole at 72 weeks 1
• 5-year mycological cure: 46% vs 13% for itraconazole 1
• Relapse rates significantly lower: 23% vs 53% mycological relapse compared to itraconazole 1

Clinical Pearls

• Optimal clinical effect appears months after treatment cessation due to time required for healthy nail outgrowth 2, 5
• Terbinafine persists in nails for up to 30 weeks after treatment completion, maintaining fungicidal effect 1, 5
• Detected in nail within 1 week of starting therapy 1
• Photosensitivity can occur: Advise patients to minimize sun and artificial UV exposure 2
• Pregnancy category: Not recommended during pregnancy without discussion; passes into breast milk 2
• Emerging resistance: Terbinafine resistance is increasing (0.63% in 2013 to 1.3% in 2021), with MIC as low as 0.015 μg/mL conferring clinical resistance 6